

Susan C Bates

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/817209/publications.pdf>

Version: 2024-02-01

111
papers

6,525
citations

109321

35
h-index

66911

78
g-index

166
all docs

166
docs citations

166
times ranked

9007
citing authors

#	ARTICLE	IF	CITATIONS
1	Revisiting the role of ABC transporters in multidrug-resistant cancer. <i>Nature Reviews Cancer</i> , 2018, 18, 452-464.	28.4	1,181
2	Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 5410-5417.	1.6	687
3	Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. <i>Blood</i> , 2001, 98, 2865-2868.	1.4	458
4	Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. <i>Blood</i> , 2011, 117, 5827-5834.	1.4	428
5	Epigenetic Therapies for Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 650-663.	27.0	289
6	Randomized Phase III Trial of Pegvorhialuronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3185-3194.	1.6	233
7	Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 997-1008.	2.4	215
8	T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. <i>Blood</i> , 2004, 103, 4636-4643.	1.4	188
9	Projected changes in tropical cyclone activity under future warming scenarios using a high-resolution climate model. <i>Climatic Change</i> , 2018, 146, 547-560.	3.6	142
10	Epigenetic Modifiers: Basic Understanding and Clinical Development. <i>Clinical Cancer Research</i> , 2009, 15, 3918-3926.	7.0	135
11	Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2018, 36, 1594-1602.	1.6	122
12	Growth regulation of human breast carcinoma occurs through regulated growth factor secretion. <i>Journal of Cellular Biochemistry</i> , 1987, 35, 1-16.	2.6	111
13	Increased <i>MDR1</i> Expression in Normal and Malignant Peripheral Blood Mononuclear Cells Obtained from Patients Receiving Depsipeptide (FR901228, FK228, NSC630176). <i>Clinical Cancer Research</i> , 2006, 12, 1547-1555.	7.0	97
14	Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression. <i>Journal of Cellular Biochemistry</i> , 1997, 65, 513-526.	2.6	87
15	Tumor Growth Rates Derived from Data for Patients in a Clinical Trial Correlate Strongly with Patient Survival: A Novel Strategy for Evaluation of Clinical Trial Data. <i>Oncologist</i> , 2008, 13, 1046-1054.	3.7	81
16	Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistance. <i>Nature Communications</i> , 2021, 12, 2804.	12.8	77
17	Neoadjuvant Treatment for Pancreatic Cancer. <i>Seminars in Oncology</i> , 2019, 46, 19-27.	2.2	76
18	Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. <i>British Journal of Haematology</i> , 2010, 148, 256-267.	2.5	74

#	ARTICLE	IF	CITATIONS
19	Amplification of 4q21-q22 and theMXR gene in independently derived mitoxantrone-resistant cell lines. , 2000, 27, 110-116.		73
20	MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor. Blood, 2013, 121, 4115-4125.	1.4	69
21	<p>BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects</p>. Cancer Management and Research, 2020, Volume 12, 2731-2742.	1.9	69
22	Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis. Lancet Oncology, The, 2017, 18, 143-154.	10.7	68
23	Contribution of glutathione and glutathione-dependent enzymes in the reversal of adriamycin resistance in colon carcinoma cell lines. International Journal of Cancer, 1991, 49, 688-695.	5.1	63
24	Reversal of Multidrug Resistance: Lessons from Clinical Oncology. Novartis Foundation Symposium, 0, , 83-102.	1.1	59
25	Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers. Clinical Cancer Research, 2013, 19, 4499-4507.	7.0	55
26	Romidepsin in peripheral and cutaneous Tâ€œll lymphoma: mechanistic implications from clinical and correlative data. British Journal of Haematology, 2015, 170, 96-109.	2.5	51
27	Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma. Clinical Cancer Research, 2015, 21, 2096-2106.	7.0	48
28	Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer. Cell Cycle, 2011, 10, 3119-3128.	2.6	45
29	Current challenges in the management of breast cancer brain metastases. Seminars in Oncology, 2017, 44, 85-100.	2.2	44
30	Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: InÂvitro and inÂvivo. Cancer Letters, 2018, 424, 19-29.	7.2	42
31	Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2. Oncotarget, 2014, 5, 4529-4542.	1.8	41
32	Changing the Paradigms of Treatment in Peripheral T-cell Lymphoma: From Biology to Clinical Practice. Clinical Cancer Research, 2014, 20, 5240-5254.	7.0	40
33	Internal climate variability and projected future regional steric and dynamic sea level rise. Nature Communications, 2018, 9, 1068.	12.8	40
34	Histone deacetylase inhibitorâ€œmediated cell death is distinct from its global effect on chromatin. Molecular Oncology, 2014, 8, 1379-1392.	4.6	39
35	Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung. Anti-Cancer Drugs, 2018, 29, 457-465.	1.4	39
36	Pancreatic Cancer: â€œA Riddle Wrapped in a Mystery inside an Enigmaâ€œ. Clinical Cancer Research, 2017, 23, 1629-1637.	7.0	38

#	ARTICLE	IF	CITATIONS
37	Current Status of HDAC Inhibitors in Cutaneous T-cell Lymphoma. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 805-819.	6.7	38
38	Increased epidermal growth factor receptor in an estrogen-responsive, adriamycin-resistant MCF-7 cell line. <i>Journal of Cellular Physiology</i> , 1993, 157, 110-118.	4.1	37
39	Drug Development: Portals of Discovery. <i>Clinical Cancer Research</i> , 2012, 18, 23-32.	7.0	37
40	Developing Precision Medicine in a Global World. <i>Clinical Cancer Research</i> , 2014, 20, 1419-1427.	7.0	36
41	FR901228 causes mitotic arrest but does not alter microtubule polymerization. <i>Anti-Cancer Drugs</i> , 2000, 11, 445-454.	1.4	35
42	Expression of the Multidrug Resistance-Associated Protein Gene in Refractory Lymphoma: Quantitation by a Validated Polymerase Chain Reaction Assay. <i>Blood</i> , 1997, 89, 3795-3800.	1.4	32
43	An ATP-binding cassette gene (ABCG3) closely related to the multidrug transporter ABCG2 (MXR/ABCP) has an unusual ATP-binding domain. <i>Mammalian Genome</i> , 2001, 12, 86-88.	2.2	32
44	Effects of <i>UGT1A1</i> genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 461-473.	2.0	32
45	Clinical Reversal of Multidrug Resistance. <i>Stem Cells</i> , 1996, 14, 56-63.	3.2	31
46	Targeting Translation of mRNA as a Therapeutic Strategy in Cancer. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 219-227.	2.3	31
47	Emerging Therapeutic Implications of STK11 Mutation: Case Series. <i>Oncologist</i> , 2020, 25, 733-737.	3.7	31
48	Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology Meeting. <i>Oncologist</i> , 2016, 21, 261-268.	3.7	30
49	Advancing Clinical Trials to Streamline Drug Development. <i>Clinical Cancer Research</i> , 2015, 21, 4527-4535.	7.0	29
50	Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration. <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 40, 245-250.	2.3	28
51	Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy. <i>Leukemia and Lymphoma</i> , 2018, 59, 880-887.	1.3	28
52	Continuing a Cancer Treatment Despite Tumor Growth May Be Valuable: Sunitinib in Renal Cell Carcinoma as Example. <i>PLoS ONE</i> , 2014, 9, e96316.	2.5	26
53	Exploring the Impact of Dust on North Atlantic Hurricanes in a High-Resolution Climate Model. <i>Geophysical Research Letters</i> , 2019, 46, 1105-1112.	4.0	26
54	Loss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitors. <i>Cell Cycle</i> , 2013, 12, 2829-2838.	2.6	24

#	ARTICLE	IF	CITATIONS
55	Reversal of ABCB1 mediated efflux by imatinib and nilotinib in cells expressing various transporter levels. <i>Chemico-Biological Interactions</i> , 2017, 273, 171-179.	4.0	23
56	UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 450-460.	2.0	19
57	Adrenocortical Cancer: A Molecularly Complex Disease Where Surgery Matters. <i>Clinical Cancer Research</i> , 2016, 22, 4989-5000.	7.0	15
58	A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on Veterans treated with abiraterone and enzalutamide. <i>Seminars in Oncology</i> , 2019, 46, 351-361.	2.2	15
59	Targeting mitochondrial hexokinases increases efficacy of histone deacetylase inhibitors in solid tumor models. <i>Experimental Cell Research</i> , 2019, 375, 106-112.	2.6	15
60	Prevention of Venous Thromboembolism in Pancreatic Cancer: Breaking Down a Complex Clinical Dilemma. <i>Oncologist</i> , 2020, 25, 132-139.	3.7	15
61	Metastatic and recurrent adrenocortical cancer is not defined by its genomic landscape. <i>BMC Medical Genomics</i> , 2020, 13, 165.	1.5	15
62	Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras. <i>Oncotarget</i> , 2016, 7, 69804-69815.	1.8	14
63	Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials. <i>Leukemia and Lymphoma</i> , 2017, 58, 2335-2341.	1.3	13
64	Evidence generation and reproducibility in cell and gene therapy research: A call to action. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 22, 11-14.	4.1	13
65	R-Loop-Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin. <i>Molecular Cancer Research</i> , 2021, 19, 1361-1374.	3.4	12
66	Pancreatic Cancer: Challenge and Inspiration. <i>Clinical Cancer Research</i> , 2017, 23, 1628-1628.	7.0	11
67	Botryllamide G is an ABCG2 inhibitor that improves lapatinib delivery in mouse brain. <i>Cancer Biology and Therapy</i> , 2020, 21, 223-230.	3.4	10
68	Therapies with Diverse Mechanisms of Action Kill Cells by a Similar Exponential Process in Advanced Cancers. <i>Cancer Research</i> , 2014, 74, 4653-4662.	0.9	9
69	Refining Immunotherapy Approvals. <i>Clinical Cancer Research</i> , 2017, 23, 4948-4949.	7.0	9
70	Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma. <i>Oncolmmunology</i> , 2022, 11, 2066767.	4.6	9
71	Histone Deacetylase Inhibitors in Combinations: Will the Preclinical Promises Be Kept?. <i>Cancer Journal (Sudbury, Mass)</i> , 2007, 13, 80-83.	2.0	7
72	New drug for pancreatic cancer highlights the dual effect of regulatory approvals. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 205-206.	27.6	7

#	ARTICLE	IF	CITATIONS
73	Clinical Trials in Pancreatic Cancer: A Long Slog. <i>Oncologist</i> , 2017, 22, 1424-1426.	3.7	7
74	Two decades of research toward the treatment of locally advanced and metastatic pancreatic cancer: Remarkable effort and limited gain. <i>Seminars in Oncology</i> , 2021, 48, 34-46.	2.2	7
75	New ABC transporters in multi-drug resistance. <i>Expert Opinion on Therapeutic Targets</i> , 2000, 4, 561-580.	1.0	6
76	Multiple Myeloma: Multiplying Therapies. <i>Clinical Cancer Research</i> , 2016, 22, 5418-5418.	7.0	6
77	A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 565-570.	2.3	6
78	Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling Pathways. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1422-1430.	4.1	6
79	The Use and Potential of Serum Tumour Markers, New and Old. <i>Drugs</i> , 1989, 38, 9-18.	10.9	5
80	Too Many Journals. <i>Oncologist</i> , 2017, 22, 126-128.	3.7	5
81	Entinostat finds a path: A new study elucidates effects of the histone deacetylase inhibitor on the immune system. <i>Cancer</i> , 2018, 124, 4597-4600.	4.1	5
82	Drug resistant cells with very large proliferative potential grow exponentially in metastatic prostate cancer. <i>Oncotarget</i> , 2021, 12, 15-21.	1.8	5
83	Clinical Reversal of Multidrug Resistance. <i>Oncologist</i> , 1996, 1, 269-275.	3.7	5
84	ATM inhibition overcomes resistance to histone deacetylase inhibitor due to p21 induction and cell cycle arrest. <i>Oncotarget</i> , 2020, 11, 3432-3442.	1.8	5
85	Targeting KRAS and the vitamin D receptor via microtubules. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 442-444.	27.6	4
86	Endocrine Cancers: Defying the Paradigms. <i>Clinical Cancer Research</i> , 2016, 22, 4980-4980.	7.0	4
87	Gemcitabine plus nabâ€paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans. <i>Seminars in Oncology</i> , 2021, 48, 69-75.	2.2	4
88	Dual Inhibition of Histone Deacetylases and the Mechanistic Target of Rapamycin Promotes Apoptosis in Cell Line Models of Uveal Melanoma. , 2021, 62, 16.		4
89	Costâ€effectiveness of neoadjuvant <sc>FOLFIRINOX</sc> versus gemcitabine plus nabâ€paclitaxel in borderline resectable/locally advanced pancreatic cancer patients. <i>Cancer Reports</i> , 2022, 5, e1565.	1.4	4
90	Commentary: Troublesome Words, Linguistic Precision, and Medical Oncology. <i>Oncologist</i> , 2009, 14, 445-447.	3.7	3

#	ARTICLE	IF	CITATIONS
91	Conflict of Interest: An Ethical Firestorm with Consequences for Cancer Research. <i>Oncologist</i> , 2018, 23, 1391-1393.	3.7	3
92	Emergency Department Visits for Emesis Following Chemotherapy: Guideline Nonadherence, OP â€³5, and a Path Back to the Future. <i>Oncologist</i> , 2021, 26, 274-276.	3.7	3
93	Equipoise, drug development, and biliary cancer. <i>Cancer</i> , 2022, 128, 944-949.	4.1	3
94	Romidepsin Therapy Over 5 Years in a Clinical Settingâ€”Real-world Experience. <i>JAMA Oncology</i> , 2016, 2, 794.	7.1	2
95	Accrual, Publication Bias, and the Coronavirus in 2020. <i>Oncologist</i> , 2020, 25, e1001-e1002.	3.7	2
96	Positive attitudes toward clinical trials among military veterans leaves unanswered questions about poor trial accrual. <i>Seminars in Oncology</i> , 2021, 48, 130-140.	2.2	2
97	A Histone Deacetylase Inhibitor Induces Acetyl-CoA Depletion Leading to Lethal Metabolic Stress in RAS-Pathway Activated Cells. <i>Cancers</i> , 2022, 14, 2643.	3.7	2
98	Disruptive Immunology. <i>Clinical Cancer Research</i> , 2016, 22, 1844-1844.	7.0	1
99	Publish or Perish v2. <i>Oncologist</i> , 2019, 24, 723-724.	3.7	1
100	PDâ€”1 Pandemonium at the American Association for Cancer Research Annual Meeting. <i>Oncologist</i> , 2019, 24, 571-573.	3.7	1
101	Antibiotics and Imiquimod for Cutaneous Tâ€”Cell Lymphoma in Veterans: A Patient Population with Agent Orange Exposure. <i>Oncologist</i> , 2021, 26, 727.	3.7	1
102	A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma. <i>Cancer</i> , 2002, 94, 2333-2343.	4.1	1
103	VA Cancer Research: A Legacy and A Future. <i>Seminars in Oncology</i> , 2019, 46, 305-307.	2.2	1
104	Expression of the Multidrug Resistance-Associated Protein Gene in Refractory Lymphoma: Quantitation by a Validated Polymerase Chain Reaction Assay. <i>Blood</i> , 1997, 89, 3795-3800.	1.4	1
105	Supreme Court and the Practice of Oncology. <i>Oncologist</i> , 2022, 27, 427-427.	3.7	1
106	How Do Cancer Cells Die?. <i>Clinical Cancer Research</i> , 2015, 21, 5014-5014.	7.0	0
107	Phase I Testing: 60 Years in the Making. <i>Clinical Cancer Research</i> , 2016, 22, 2612-2612.	7.0	0
108	Base Pairs to Populations. <i>Clinical Cancer Research</i> , 2017, 23, 2610-2610.	7.0	0

#	ARTICLE	IF	CITATIONS
109	Adenocarcinoma of the Pancreas: Past, Present, Future. <i>Seminars in Oncology</i> , 2021, 48, 1.	2.2	0
110	Epigenetic Modulation and Therapy of Lymphoid Malignancies. <i>Blood</i> , 2010, 116, SCI-30-SCI-30.	1.4	0
111	Assessment of Tumor Growth (g) and Regression (d) Rate Constants in Patients with Multiple Myeloma (MM) Shows That the Superiority of Bortezomib with Liposomal Doxorubicin (PLD+B) Over Bortezomib Alone (B) Is a Result of Reduced Growth of Refractory Tumor Cells and Not of Higher Regression Rates, and Provides An Earlier Efficacy Endpoint That Allows for Comparison Across Trials. <i>Blood</i> , 2011, 118, 5113-5113.	1.4	0